Restless Legs and Iron: When to See a Doctor

What Is Restless Legs Syndrome and Why Does Iron Matter?

Restless legs syndrome is a neurological sensory-motor condition defined by an irresistible urge to move the legs, usually accompanied by uncomfortable sensations that worsen at rest and improve with movement. Iron sits at the center of the biology: dopamine synthesis in the brain depends on iron-containing enzymes, and when brain iron stores drop, the dopaminergic pathways that regulate sensory gating in the spinal cord malfunction. Research published in Sleep Medicine showed that cerebrospinal fluid ferritin was significantly lower in RLS patients compared with controls, confirming that brain iron, not just serum iron, drives the condition.

Women carry a disproportionate burden. RLS is roughly 1.5 to 2 times more common in women than in men, and the gap widens during life stages that drain iron: menstruation, pregnancy, and the perimenopause transition.

The Iron-Dopamine Connection

Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine production. When ferritin falls, tyrosine hydroxylase activity drops, dopamine availability in the substantia nigra and striatum declines, and the inhibitory tone on spinal sensory neurons is lost. The legs signal discomfort even when there is no structural injury. A 2014 review in Sleep Medicine Reviews described this as "brain iron deficiency," distinct from systemic anemia, because symptoms can appear even when hemoglobin is entirely normal.

Why Ferritin Matters More Than Hemoglobin

Many women are told their blood counts are "normal" and dismissed. The critical number is serum ferritin, the storage form of iron. The American Academy of Sleep Medicine and RLS clinical guidelines recommend a ferritin target above 75 ng/mL for RLS management, and some neurologists treating refractory RLS aim for 100 ng/mL or higher. A ferritin of 18 ng/mL may be flagged as "within range" on a lab report yet still be low enough to perpetuate nightly symptoms.

Who Gets Iron-Deficiency RLS? A Life-Stage Guide

Reproductive Years and Heavy Periods

If you have heavy menstrual bleeding (defined clinically as losing more than 80 mL per cycle), you lose iron faster than a typical diet replaces it. The CDC estimates that iron deficiency affects approximately 10% of U.S. Women of reproductive age, but that figure rises sharply among women with menorrhagia, fibroids, or adenomyosis. Fibroids alone affect up to 80% of Black women and 70% of white women by age 50, making iron-deficiency RLS a genuinely common sequela in this group.

If your RLS started or worsened alongside heavier periods, that is a direct diagnostic signal.

Pregnancy: The Highest-Risk Period

Pregnancy is the life stage where iron-deficiency RLS is most severe and most often missed. Blood volume expands by 40 to 50%, fetal iron demand peaks in the third trimester, and dietary intake rarely keeps pace. A systematic review in Sleep Medicine Reviews found RLS prevalence of 10 to 26% during pregnancy, with symptoms typically worst between weeks 28 and 36. In most women, RLS resolves within weeks of delivery, which is strong evidence for the iron-depletion mechanism.

ACOG does not have a dedicated RLS guideline, but its iron deficiency anemia in pregnancy guidance recommends screening all pregnant women for anemia at the first prenatal visit and supplementing when ferritin is low. If you are pregnant and experiencing nightly leg discomfort, ask your midwife or OB to check serum ferritin, not just hemoglobin.

Postpartum and Lactation

Blood loss at delivery, combined with nine months of iron sharing with the fetus, can leave ferritin critically low. RLS that began in pregnancy sometimes persists postpartum when iron stores are not replenished. Studies tracking postpartum women show ferritin can remain depleted for three to six months after delivery, especially in women who breastfeed exclusively and do not supplement.

If you had RLS in pregnancy and it has not resolved by six to eight weeks postpartum, request a ferritin level at your postpartum visit.

Perimenopause

The perimenopause transition brings erratic, sometimes heavier cycles before periods stop entirely. This irregular iron loss, layered onto years of reproductive-age depletion, can push ferritin low enough to trigger or worsen RLS for the first time in your 40s. Hormone fluctuation during perimenopause also appears to modulate dopamine receptor sensitivity independently of iron, which may explain why some women develop RLS in perimenopause even with borderline-adequate ferritin.

The Menopause Society (formerly NAMS) acknowledges that sleep disruption in perimenopause is multifactorial, and RLS is listed among the contributors that clinicians should actively screen for rather than attributing all sleep complaints to vasomotor symptoms alone.

Postmenopause

After periods stop, the monthly iron drain disappears, and RLS driven purely by menstrual loss often improves. A postmenopausal woman with new or worsening RLS warrants investigation for other causes of iron depletion: gastrointestinal bleeding, celiac disease, or long-term proton pump inhibitor use that impairs iron absorption. New RLS after menopause should not be attributed to hormones without checking ferritin first.

What Restless Legs Actually Feels Like

Symptoms vary enough that many women do not recognize them as RLS. The diagnostic criteria require all four of these features, as defined by the International Restless Legs Syndrome Study Group (IRLSSG):

1. An urge to move the legs, usually accompanied by uncomfortable sensations.
2. The urge starts or worsens during rest or inactivity.
3. The urge is partially or fully relieved by movement.
4. The urge is worse in the evening or at night than during the day.

Common descriptors women use include "creeping," "crawling," "pulling," "itching deep in the bone," or "electric." Some women describe it simply as an unbearable need to stretch. The sensations sit in the calves most often, but thighs, feet, and even arms can be involved.

Periodic limb movements of sleep (PLMS), involuntary leg jerks during sleep, accompany RLS in about 80% of cases and are often noticed first by a bed partner.

When Should You Worry? Red Flags That Mean See a Doctor Now

Mild, occasional restless legs that respond to stretching and a warm bath are worth monitoring. The following situations need medical attention promptly.

Nightly Symptoms

If the urge to move your legs is happening every night and interrupting sleep, the condition has crossed into moderate-to-severe RLS. Validated severity scoring with the IRLS Scale classifies nightly, sleep-disrupting symptoms as severe, and this grade carries real consequences: chronic sleep deprivation is linked to cardiovascular risk, mood disorders, and impaired immune function.

Pregnancy

Any leg discomfort that fits the four IRLSSG criteria during pregnancy warrants a same-visit ferritin check. Untreated moderate-to-severe RLS in pregnancy is associated with worse sleep quality, higher rates of postpartum depression, and in some studies, preterm birth risk. Do not wait for your next scheduled appointment.

Signs of Anemia Alongside RLS

If you have restless legs plus fatigue that does not improve with rest, pallor, shortness of breath on minimal exertion, heart palpitations, or cold hands and feet, you may have iron-deficiency anemia rather than isolated low ferritin. Anemia during heavy-period years or pregnancy is a reason to be seen within days, not weeks.

Symptoms That Started with a New Medication

Several medications worsen or trigger RLS: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antipsychotics, antihistamines, and some antiemetics used in pregnancy (like metoclopramide). If your legs became restless shortly after starting a new drug, flag it with your prescriber.

No Response to Iron After 8 to 12 Weeks

If your ferritin was low, you have been supplementing for three months, your ferritin is now above 75 ng/mL, and symptoms persist, secondary causes need evaluation: renal disease, peripheral neuropathy, or primary RLS requiring dopaminergic treatment.

How Is Iron-Deficiency RLS Diagnosed?

Diagnosis is clinical first, then confirmed with labs. There is no imaging or genetic test required for a straightforward diagnosis.

The Lab Panel You Should Request

Ask your provider for:

• Serum ferritin (the most sensitive iron marker for RLS; target above 75 ng/mL)
• Serum iron and total iron-binding capacity (TIBC) or transferrin saturation
• Complete blood count (CBC) with hemoglobin and mean corpuscular volume (MCV)
• C-reactive protein (CRP), because ferritin is an acute-phase reactant and can appear falsely normal during inflammation

A 2020 practice guideline from the American Academy of Neurology and the American Academy of Sleep Medicine recommends checking serum ferritin in all patients with RLS before initiating any treatment, including in those with no obvious reason for iron deficiency.

Sleep Study Considerations

Polysomnography (PSG) is not required to diagnose RLS but may be ordered to quantify PLMS, rule out obstructive sleep apnea (common in perimenopause and postmenopause), or document severity before initiating prescription treatment.

Treatment Options for Iron-Deficiency RLS

Oral Iron Supplementation

First-line treatment when ferritin is below 75 ng/mL is oral iron. A randomized controlled trial published in Sleep Medicine found that oral ferrous sulfate 325 mg twice daily significantly improved IRLS scores at 12 weeks compared with placebo in patients with ferritin below 45 ng/mL. Taking iron with 250 mg of vitamin C improves absorption. Avoid taking it with calcium, antacids, or dairy within two hours.

Common side effects are constipation and nausea. Ferrous gluconate or iron bisglycinate tend to be gentler on the gut if sulfate is not tolerated.

Target at least eight to twelve weeks of supplementation and recheck ferritin before declaring treatment a failure.

Intravenous Iron

IV iron is appropriate when oral iron causes intolerable GI side effects, when absorption is impaired (celiac disease, post-bariatric surgery, inflammatory bowel disease), or when ferritin needs rapid correction, as in late pregnancy with severe RLS. A double-blind RCT of IV ferric carboxymaltose published in Sleep Medicine showed significant improvement in IRLS scores at four weeks versus placebo, with effects sustained to twelve weeks. IV iron is administered in an infusion center and generally requires a single session.

Lifestyle and Non-Drug Measures

Several strategies reduce symptom severity while iron is being restored:

• Avoid caffeine, alcohol, and nicotine, all of which worsen RLS.
• Moderate aerobic exercise (30 minutes, three to five times per week) modestly reduces symptoms per a 2006 study in Sleep Medicine.
• Pneumatic compression devices are approved by the FDA as a non-drug option and showed symptom benefit in a 2014 trial in Sleep Medicine.
• Warm baths before bed and counter-stimulation (massage, cold packs) offer short-term relief.

Prescription Medications (When Iron Is Not Enough)

If ferritin is adequate and symptoms persist, clinicians may add:

• Gabapentin enacarbil (Horizant) or pregabalin: FDA-approved for moderate-to-severe RLS; preferred over dopamine agonists for long-term use because they carry no risk of augmentation.
• Pramipexole or ropinirole: dopamine agonists that work quickly but carry a risk of augmentation (worsening severity over time) with prolonged use.

Medication choice is highly life-stage dependent. In pregnancy, most RLS medications are avoided; IV iron is preferred. Discuss any prescription option with your provider given your specific hormonal and reproductive status.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Iron supplementation is safe in pregnancy and often necessary. ACOG Practice Bulletin 233 on anemia in pregnancy recommends routine iron supplementation starting at the first prenatal visit, with doses titrated to ferritin and hemoglobin. IV iron formulations (ferric carboxymaltose, low-molecular-weight iron dextran, ferric gluconate) are considered acceptable in the second and third trimesters when oral iron fails; the first trimester is generally avoided due to limited data on fetal organogenesis.

Prescription RLS drugs carry meaningful risks in pregnancy. Dopamine agonists (pramipexole, ropinirole) are not FDA-approved for use in pregnancy and have insufficient human safety data. Gabapentin crosses the placenta and has been associated with neonatal withdrawal and possible risk of preterm birth in some observational data, though causality is debated. The default position for any pregnancy RLS medication question is: iron first, specialist consultation before anything else.

Lactation

Oral iron supplementation at standard doses does not meaningfully increase breast milk iron concentration and is safe during breastfeeding. The National Institutes of Health Office of Dietary Supplements notes that breast milk iron is tightly regulated by maternal physiology regardless of maternal iron intake, but maternal supplementation remains important for restoring depleted stores.

Gabapentin transfers into breast milk at low concentrations, but infant exposure and sedation risk require discussion with your provider. Dopamine agonists suppress prolactin and can reduce milk supply; they should be avoided while breastfeeding.

Contraception

Iron-deficiency RLS is not itself a contraindication to any contraceptive method. However, combined hormonal contraceptives (pills, patch, ring) often reduce menstrual blood loss by 40 to 50%, which can raise ferritin over time and secondarily improve RLS in women whose deficiency is driven by heavy periods. This is a clinically meaningful benefit worth discussing with your provider if you are also looking for cycle management.

A Practical Framework: Which Women Should Be Screened for Iron-Deficiency RLS?

WomanRx recommends proactive ferritin screening in any woman who presents with leg discomfort at night plus at least one of the following iron-drain factors. This framework is not a published guideline but reflects synthesis of the IRLSSG diagnostic criteria, ACOG iron guidance, and AAN/AASM RLS management recommendations:

| Iron-Drain Factor | Why It Matters | |---|---| | Heavy menstrual bleeding (>80 mL/cycle) | Monthly loss exceeds dietary repletion | | Fibroids or adenomyosis | Structural cause of menorrhagia | | Pregnancy (any trimester) | Fetal demand peaks in third trimester | | Postpartum <6 months | Combined delivery loss and lactation drain | | Celiac disease or IBD | Malabsorption limits oral iron uptake | | Vegan or vegetarian diet | Non-heme iron is 5-15% absorbed vs. 15-35% for heme iron | | Chronic PPI or antacid use | Gastric acid required for iron absorption | | Recent bariatric surgery | Bypass reduces duodenal absorption site |

If you have any of these and nightly leg symptoms, ask for a ferritin level at your next visit. Do not accept a normal CBC alone as reassurance.

Who Is This Right For and Who Should Be Cautious?

Women Who Are Likely to Benefit from Iron-First Treatment

• Premenopausal women with heavy periods and ferritin below 75 ng/mL
• Pregnant women in any trimester with IRLSSG-criteria symptoms
• Women with recent bariatric surgery or known celiac disease and new RLS
• Vegans and vegetarians who have never been screened for iron status

Women Who Need Specialist Referral, Not Just Iron Repletion

• Women whose RLS persists after ferritin exceeds 100 ng/mL for at least three months
• Women with a family history of RLS (genetic primary RLS is distinct from iron-deficiency RLS and often needs dopaminergic treatment)
• Women with renal insufficiency (kidney disease significantly raises RLS risk through a different mechanism)
• Women with severe, nightly symptoms that are causing moderate-to-severe sleep disruption regardless of iron status

An Honest Note on the Evidence Gap

Women make up the majority of RLS patients, yet most foundational RLS drug trials enrolled more men than women or did not stratify results by sex. Dosing recommendations for dopamine agonists and gabapentinoid agents are not sex-stratified in current FDA labeling, even though women generally have lower body weight, different renal clearance trajectories, and different hormonal contexts that could alter drug response. This is a real gap. When your provider recommends starting at the lowest available dose and titrating slowly, that approach is both guideline-consistent and appropriate for the sex-specific PK differences that have not been fully characterized.

Frequently Asked Questions